Novartis gene therapy brings in $160 million, beating expectations

Novartis gene therapy brings in $160 million, beating expectations

By REBECCA ROBBINS AND DAMIAN GARDE

RUBY WALLAU FOR STAT

The gene therapy, Zolgensma, carries a record price tag of $2.1 million, or an annualized cost of $425,000 per year for five years.

READ MORE